| Bioactivity | Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. | ||||||||||||
| Target | TrkA | ||||||||||||
| Invitro | Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1]. | ||||||||||||
| Name | Tavilermide | ||||||||||||
| CAS | 263251-78-1 | ||||||||||||
| Formula | C24H32N6O11 | ||||||||||||
| Molar Mass | 580.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85. |